Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $424.15M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.60M
Average 0.51M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -43.6% | +89.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -43.6% over three years. Forward estimates point to Revenue at +89.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Biogen Inc. NASDAQ:BIIB | $37.46B | $253.40 | Undervalued | 21.1 | +48.55% |
Denali Therapeutics Inc. NASDAQ:DNLI | $3.00B | $18.74 | Not rated | -8.7 | +2.97% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | +8.44% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | $2.13 | Not rated | -2.9 | -30.82% |
Anavex Life Sciences Corp. NASDAQ:AVXL | $86.53M | $0.93 | Not rated | -5.9 | -78.86% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Cognition Therapeutics, Inc. NASDAQ:CGTX | $64.65M | $0.68 | Not rated | -6.4 | -58.56% |
ProMIS Neurosciences, Inc. NASDAQ:PMN | $29.50M | $3.29 | Not rated | -0.6 | +22.03% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $15.48M | $0.21 | Not rated | -1.3 | +37.95% |
Continue the stock analysis
Jump to another research area for this company.